FDA Grants Accelerated Approval to Blinatumomab for the Treatment of B-cell Precursor ALL

It is indicated in adult and paediatric patients in first or second complete remission with minimal residual disease

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply